Size | Price | Stock | Qty |
---|---|---|---|
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
ABT-724 isa novel, potent and highly selective dopamine D4 receptor agonist with an EC50 of 12.4 nM. It was created as a potential medication to treat erectile dysfunction. It has a good side-effect profile and may be helpful in treating erectile dysfunction.
Targets |
Human dopamine D4 receptor ( EC50 = 12.4 nM ); Rat dopamine D4 receptor ( EC50 = 14.3 nM ); Ferret dopamine D4 receptor ( EC50 = 23.2 nM )
|
---|---|
ln Vitro |
ABT-724 displays a selective biochemical profile, as demonstrated by its lack of binding affinity for over 70 neurotransmitter/uptake/ion channels, such as D2, D3, or D5 receptors, at concentrations up to 10 μM. There's a low affinity (Ki = 2780 nM) for 5-HT1A receptors. At concentrations of 10 μM, ABT-724 does not inhibit PDE activity of PDE1, PDE5, or PDE6[1].
|
ln Vivo |
ABT-724 (8.8 μg/kg; subcutaneous injection; daily; for 5 days; male adult Wistar rats) treatment dose-dependently promotes penile erection when administered subcutaneously to conscious rats[1].
|
Animal Protocol |
Male adult Wistar rats (~300 g)
8.8 μg/kg Subcutaneous injection; daily; for 5 days |
References | |
Additional Infomation |
2-[[4-(2-pyridinyl)-1-piperazinyl]methyl]-1H-benzimidazole is a member of pyridines and a member of piperazines.
|
Molecular Formula |
C17H19N5
|
---|---|
Molecular Weight |
402.74908
|
Exact Mass |
293.164
|
Elemental Analysis |
C, 69.60; H, 6.53; N, 23.87
|
CAS # |
70006-24-5
|
Related CAS # |
ABT-724 trihydrochloride; 587870-77-7; 587870-77-7 (HCl); 70006-24-5
|
PubChem CID |
5025739
|
Appearance |
Solid powder
|
Density |
1.275g/cm3
|
Boiling Point |
548.6ºC at 760 mmHg
|
Flash Point |
285.6ºC
|
Index of Refraction |
1.687
|
LogP |
2.283
|
Hydrogen Bond Donor Count |
1
|
Hydrogen Bond Acceptor Count |
4
|
Rotatable Bond Count |
3
|
Heavy Atom Count |
22
|
Complexity |
355
|
Defined Atom Stereocenter Count |
0
|
SMILES |
C1=CC=C2C(=C1)NC(=N2)CN3CCN(CC3)C4=CC=CC=N4
|
InChi Key |
FRPJGTNLZNXQEX-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C17H19N5/c1-2-6-15-14(5-1)19-16(20-15)13-21-9-11-22(12-10-21)17-7-3-4-8-18-17/h1-8H,9-13H2,(H,19,20)
|
Chemical Name |
2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]-1H-benzimidazole
|
Synonyms |
ABT 724; ABT724; ABT-724; UNII-4WV2575JWT
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.4829 mL | 12.4146 mL | 24.8293 mL | |
5 mM | 0.4966 mL | 2.4829 mL | 4.9659 mL | |
10 mM | 0.2483 mL | 1.2415 mL | 2.4829 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Proerectile effect of ABT-724 in conscious Wistar rats after s.c. administration. Proc Natl Acad Sci U S A . 2004 Apr 27;101(17):6758-63. td> |
Proerectile effect of ICV injections of ABT-724 and apomorphine (3 nmol) via chronically implanted cannulas in conscious Wistar rats. Proc Natl Acad Sci U S A . 2004 Apr 27;101(17):6758-63. td> |
Original recording of ICP responses in an awake freely moving rat after s.c. administration of ABT-724 (0.0025 μmol/kg, s.c.). Proc Natl Acad Sci U S A . 2004 Apr 27;101(17):6758-63. td> |